title: Imatinib for the treatment of patients with unresectable or metastatic malignant KIT-positive gastrointestinal stromal tumours: an open-label Belgian trial.
abstract: BACKGROUND
  Gastrointestinal stromal tumours (GIST) are the most common mesenchymal tumours of the gastrointestinal tract. They are defined immunohistologically as KIT positive tumours. The only effective treatment for malignant GIST was surgery until 2000. Imatinib mesylate (STI571, Glivec) has shown substantial anticancer activity in patients with metastatic or unresectable GIST.
  
  
  METHODS
  57 patients who were diagnosed with unresectable or metastatic malignant GIST were entered into this study. The patients were given 400 mg Glivec orally once daily. The dose could be increased to 600 mg orally once daily and then to 400 mg twice daily if tumour progression was noticed. Daily treatment was interrupted or dose was decreased only in the case of limiting toxicities. We evaluated the tumour response and the safety of the drug.
  
  
  RESULTS
  85% of GIST patients showed a partial response or stable disease after 8 weeks of treatment with imatinib. The main side effects were nausea, vomiting, anorexia, skin rash, periorbital oedema and diarrhea.
  
  
  CONCLUSIONS
  This study confirms that imatinib is an active agent against malignant GIST with manageable toxicities.
authors.affiliation: Department of General Medical Oncology, Catholic University of Leuven, Leuven Cancer Institute, Leuven, Belgium. hans.prenen@uz.kuleuven.be
authors.forename: Hans
authors.initials: H
authors.lastname: Prenen
authors.forename: Herlinde
authors.initials: H
authors.lastname: Dumez
authors.forename: Cristiana
authors.initials: C
authors.lastname: Stefan
authors.forename: Ann
authors.initials: A
authors.lastname: Hoeben
authors.forename: Carine
authors.initials: C
authors.lastname: Wouters
authors.forename: Marie-Anne
authors.initials: MA
authors.lastname: Van Lierde
authors.forename: Raf
authors.initials: R
authors.lastname: Sciot
authors.forename: Allan T
authors.initials: AT
authors.lastname: van Oosterom
authors.forename: Marc
authors.initials: M
authors.lastname: Peeters
authors.forename: Marc
authors.initials: M
authors.lastname: Polus
authors.forename: Lionel
authors.initials: L
authors.lastname: Duck
authors.forename: Thierry
authors.initials: T
authors.lastname: Gil
authors.forename: Patrick
authors.initials: P
authors.lastname: Schöffski
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001530:Belgium; D001549:Benzamides; D005260:Female; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010879:Piperazines / Q000627:therapeutic use*; D019009:Proto-Oncogene Proteins c-kit / Q000032:analysis; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit